Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etodolac injection - Ipca Laboratories

Next Previous
Drug Profile

Etodolac injection - Ipca Laboratories

Alternative Names: Etova-AQ; MACRE-09

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ipca Laboratories
  • Class Antirheumatics; Indoleacetic acids; Indoles; Nonsteroidal anti-inflammatories
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Postoperative pain

Most Recent Events

  • 04 May 2017 Ipca Laboratories plans a phase IV trial for Postoperative pain in India (CTRI2017-03-008275)
  • 15 Nov 2011 Ipca Laboratories completes a phase III trial in Post-operative pain in India (CTRI-2010-091-000437)
  • 01 Jul 2010 Phase-III clinical trials in Postoperative pain in India (IM)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top